SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD Chimeric Monoclonal Antibody

Severe acute respiratory syndrome coronavirus (SARS-CoV) spike glycoprotein, also known as the surface glycoprotein, is a viral structural protein encoded by the S gene in SARS-CoV RNA that contains the receptor binding domain (RBD).{53462} SARS-CoV is a member of the Betacoronavirus genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.{53459,53461} SARS-CoV spike glycoprotein is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is composed of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.{46767,46768,49561} The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.{46768,49525} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.{46768,46767,49525,49561} SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.{53461} Cayman's SARS-CoV/SARS-CoV-2 Spike Glycoprotein RBD Chimeric Monoclonal Antibody (Clone D005) is composed of human IgG1? constant domains and variable regions from a mouse immunized with purified recombinant SARS-CoV spike glycoprotein RBD. It can be used for ELISA.